Li Chang-Ling, Yang Jin-Gang, Lin Di, Zhao Yong-Shan, Liu Shuo, Xing Si-Ning, Zhao Song, Chen Cong-Qin, Jiang Zhi-Ming, Pu Fei-Fei, Cao Jian-Ping, Ma Dong-Chu
Department of Experimental Medicine, General Hospital of Shenyang Military Area Command, Shenhe District, Shenyang, Liaoning, China.
School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenhe District, Shenyang, Liaoning, China.
PLoS One. 2014 Dec 8;9(12):e114389. doi: 10.1371/journal.pone.0114389. eCollection 2014.
Megakaryocytes (MKs) are one of the few cell types that become polyploid; however, the mechanisms by which these cells are designated to become polyploid are not fully understood. In this investigation, we successfully established two relatively synchronous polyploid cell models by inducing Dami and CMK cells with SP600125. We found that SP600125 induced the polyploidization of Dami and CMK cells, concomitant with the phosphorylation of ribosomal protein S6 kinase 1 (S6K1) at Thr421/Ser424 and dephosphorylation at Thr389. The polyploidization was partially blocked by H-89, a cAMP-dependent protein kinase (PKA) inhibitor, through direct binding to S6K1, leading to dephosphorylation at Thr421/Ser424 and phosphorylation at Thr389, independent of PKA. Overexpression of a rapamycin-resistant mutant of S6K1 further enhanced the inhibitory effect of LY294002 on the SP600125-induced polyploidization of Dami and CMK cells. SP600125 also induced the polyploidization of Meg-01 cells, which are derived from a patient with chronic myelogenous leukemia, without causing a significant change in S6K1 phosphorylation. Additionally, SP600125 induced the polyploidization of HEL cells, which are derived from a patient with erythroleukemia, and phosphorylation at Thr389 of S6K1 was detected. However, the polyploidization of both Meg-01 cells and HEL cells as a result of SP600125 treatment was lower than that of SP600125-induced Dami and CMK cells, and it was not blocked by H-89 despite the increased phosphorylation of S6K1 at Thr389 in both cell lines in response to H-89. Given that the Dami and CMK cell lines were derived from patients with acute megakaryocytic leukemia (AMKL) and expressed high levels of platelet-specific antigens, our data suggested that SP600125-induced polyploidization is cell-type specific, that these cell lines were more differentiated, and that phosphorylation at Thr421/Ser424 and dephosphorylation at Thr389 of S6K1 may play an important role in the SP600125-induced polyploidization of these cell lines synergistically with other signaling pathways.
巨核细胞(MKs)是少数能形成多倍体的细胞类型之一;然而,这些细胞被指定形成多倍体的机制尚未完全了解。在本研究中,我们通过用SP600125诱导Dami和CMK细胞,成功建立了两个相对同步的多倍体细胞模型。我们发现,SP600125诱导Dami和CMK细胞多倍体化,同时核糖体蛋白S6激酶1(S6K1)在Thr421/Ser424位点磷酸化,在Thr389位点去磷酸化。多倍体化被cAMP依赖性蛋白激酶(PKA)抑制剂H-89部分阻断,H-89通过直接与S6K1结合,导致Thr421/Ser424位点去磷酸化和Thr389位点磷酸化,这一过程不依赖PKA。S6K1的雷帕霉素抗性突变体的过表达进一步增强了LY294002对SP600125诱导的Dami和CMK细胞多倍体化的抑制作用。SP600125还诱导了源自慢性粒细胞白血病患者的Meg-01细胞多倍体化,且未引起S6K1磷酸化的显著变化。此外,SP600125诱导了源自红白血病患者的HEL细胞多倍体化,并检测到S6K1在Thr389位点磷酸化。然而,SP600125处理导致的Meg-01细胞和HEL细胞的多倍体化低于SP600125诱导的Dami和CMK细胞,并且尽管两种细胞系中S6K1在Thr389位点的磷酸化因H-89而增加,但多倍体化并未被H-89阻断。鉴于Dami和CMK细胞系源自急性巨核细胞白血病(AMKL)患者且表达高水平的血小板特异性抗原,我们的数据表明,SP600125诱导的多倍体化具有细胞类型特异性,这些细胞系更具分化性,并且S6K1在Thr421/Ser424位点的磷酸化和在Thr389位点的去磷酸化可能与其他信号通路协同作用,在SP600125诱导这些细胞系多倍体化过程中发挥重要作用。